Seeing Is Believing
TARS is currently covered by 6 analysts with an average price target of $84.3. This is a potential upside of $21.52 (34.28%) from yesterday's end of day stock price of $62.78.
Tarsus Pharmaceuticals 's activity chart (see below) currently has 64 price targets and 47 ratings on display. The stock rating distribution of TARS is 88.89% BUY and 11.11% HOLD.
Analysts average stock forecasts to be materialized ratio is 90% with an average time for these price targets to be met of 472.67 days.
Highest price target for TARS is $88, Lowest price target is $51, average price target is $69.5.
Most recent stock forecast was given by EDDIE HICKMAN from GUGGENHEIM on 05-Nov-2025. First documented stock forecast 10-Nov-2020.
Currently out of the existing stock ratings of TARS, 8 are a BUY (88.89%), 1 are a HOLD (11.11%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Jun-2023
$87
$26.22 (43.14%)
$84
3 months 13 days ago
(05-Nov-2025)
3/5 (60%)
$18.8 (27.57%)
457
Buy Since 27-May-2025
$88
$27.22 (44.78%)
$72
3 months 29 days ago
(20-Oct-2025)
1/2 (50%)
$16.81 (23.61%)
141
Hold Since 20-Nov-2023
$51
$-9.78 (-16.09%)
$41
9 months 13 days ago
(05-May-2025)
4/4 (100%)
$3 (6.25%)
87
Buy Since 22-Jun-2021
$58
$-2.78 (-4.57%)
$45
11 months 12 days ago
(06-Mar-2025)
3/3 (100%)
$14.43 (33.12%)
477
Buy Since 21-Dec-2021
$73
$12.22 (20.11%)
$61
11 months 23 days ago
(26-Feb-2025)
10/10 (100%)
$30.44 (71.52%)
564
What is TARS (Tarsus Pharmaceuticals ) average time for price targets to be met?
Which analyst has the current highest performing score on TARS (Tarsus Pharmaceuticals ) with a proven track record?
Which analyst has the current lower performing score on TARS (Tarsus Pharmaceuticals ) with a proven track record?
Which analyst has the most public recommendations on TARS (Tarsus Pharmaceuticals )?
Which analyst is the currently most bullish on TARS (Tarsus Pharmaceuticals )?
Which analyst is the currently most reserved on TARS (Tarsus Pharmaceuticals )?